SMi Reports: Key discussions surrounding the use of AI in Pharmaceuticals will take place at the inaugural Disruptive Technologies in Pharma conference in London on January 20 and 21.
The latest early bird discount expires on September 30. Register early at www.disruptivetech-pharma.com/PRcom3 and save £400.
Attendees will learn valuable information from the experiences of key players in the market and gain greater understanding of the overall benefits AI provides for patients. Numerous sessions scheduled for the two-day conference focus on rapidly developing AI technologies.
Highlights include:
AI for Life
The potential of A.I. in health and the opportunities across the pharma pipeline
Concrete project examples from discovery through clinical trials and commercial, leveraging fundamental AI capabilities in cheminformatics, medical imaging, and NLP.
The challenges & foundation required for data scientists to make AI opportunities a reality
Nicholas Kelley, Data Science and AI Advisor, Novartis
AI-driven systems – focusing on practicalities of implementation
Discussing the impact of AI, ML and IoT on the pharmaceutical industry
Developing AI-enabled tools for improving patient access – where do we start?
Reflecting on global challenges of implementation and outlining strategies for improved incorporation
Exploring AI for identifying patients with rare disease and achieve early diagnosis – a case study
Peter Rutherford, Global Medical Lead, Vifor Pharma
Enabling AI Driven Drug Discovery with Cutting Edge “Disruptive” Platform
Gaining first-hand insight into AI-enabled drug discovery opportunities in pharma
Reviewing the disruptive technologies landscape through the eyes of an industry expert
Reflecting on strategies for AI-driven drug discovery
Bhushan Bonde, Head of IT – Early Solution Innovation Development, UCB
Two interactive post-conference half day workshops will take place on January 22nd.
Workshop A: “Disruptive Technologies: A Roadmap to Compliance with Technical, Evidence and Regulatory Standards” led by Mark Campbell, Freelance Regulatory Expert, former NICE | 8:30 – 12:00
Workshop B: “Build, Buy or Partner: Maximising Your Digital Health Impact” led by Karl Hess, Managing Director, OnDigitalHealth Consulting | 13:00 – 17:00
A speaker list and programme highlights are available for download from the event website at www.disruptivetech-pharma.com/PRcom3
Disruptive Technologies in Pharma
20–21 January 2020
London, UK
www.disruptivetech-pharma.com/PRcom3
Contact Information:
For media enquiries contact Alia Malick on +44 (0)20 7827 6168
For delegate enquiries contact Fateja Begum on +44 (0) 20 7827 6184
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
WASHINGTON – Today, the U.S. Department of the Treasury (Treasury), as Chair of the Committee…
WASHINGTON—Today, the U.S. Department of the Treasury’s Community Development Financial Institutions Fund (CDFI Fund) and…
Washington – The findings from the annual survey of U.S. portfolio holdings of foreign securities…
WASHINGTON – The U.S. Department of the Treasury hosted a roundtable on October 30 with…
WASHINGTON – The United States and the People’s Republic of China held the sixth meeting…
WASHINGTON — Today, the Department of the Treasury’s Office of Foreign Assets Control (OFAC) sanctioned…